EMAUD, the only complete and innovative course on pharmaceutical Market Access designed around the life cycle of a drug, is starting its second academic year on October 2010.
Created and developed by Professor Mondher Toumi, at Lyon 1 University, EMAUD delivers high quality training for international students, at a time when market access has become the key driver of pharmaceutical companies’ revenue.
With contributions from key European agencies, renowned universities and leading pharmaceutical companies, EMAUD offers an ideal mix between theory and practice for results that can be applied in the real world. “We have worked a lot on how to be as close as possible to industry needs, which is the reason why we have chosen to follow the development phases throughout the course,” said Professor Toumi.
The programme, which takes place in Paris in English, is composed of five separate four-day modules across the academic year. The topics covered include: national pricing and reimbursement systems, market access for oncology and vaccinations, payer landscapes, pricing and reimbursability studies, stakeholder management, end of phase II studies, cost-effectiveness evidence for pricing-reimbursement negotiations, and epidemiology support to market access. It is of great value to students seeking to enter the field or those who simply wish to enlarge their understanding in this important area. “EMAUD offers both strong academic rigour and a business oriented perspective through a diversified panel of experienced professionals,” was the praise offered by one of last year’s students.
Understand market access and maximize the success of your drug! Enrolment is open now until 30 September: visit www.emaud.org for more information and to apply.
Launched in January 2010 at the initiative of Professor Mondher Toumi at Lyon 1 University, the programme responds to the increasing demand from industry professionals to understand global market access issues. The modular course offering can be completed in one to three years.